Drug Trial Radar · NCT07432022
A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma
Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
115
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Jun 30, 2028
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). The study consists two phases: Phase I of dose escalation and Phase II of dose expansion. Approximately 115 patients will be enrolled in this study (i.e., 5 cohorts of approximately 23 patients per cohort). Multiple EMB-07-based combination regimens will be evaluated in patients with relapsed/refractory (R/R) aggressive B-NHL (Cohort A) and patients with newly diagnosed aggressive B-NHL (Cohort B).
Conditions
- Combination Therapy
- Aggressive B-Cell Non-Hodgkin Lymphoma
- EMB07
- phaseI/II
Interventions
EMB07Drug
EMB-07 is a bispecific antibody targeting CD3 and receptor-tyrosine-kinase-like orphan receptor 1 \[ROR1\]
Rituximab/Gemcitabine/OxaliplatinDrug
Rituximab is a monoclonal antibody drug specifically targeting the CD20 antigen. Gemcitabine is a chemotherapy drug classified as an antimetabolite. Oxaliplatin is a platinum-based chemotherapy drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum tolerated dose (MTD) of EMB-07(Phase I only)Time frame: Up to 28 days
- Rate of Adverse Events (AE) and Serious Adverse Events (SAE)Time frame: From enrollment up to 30 days after the last dose
- Recommended phase II dose (RP2D) of EMB-07Time frame: Up to 28 days
- Objective Response Rate (ORR)Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aerospace Central Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.